Sangamo Therapeutics Inc - ESG Rating & Company Profile powered by AI
The webpage includes a Q&A section on Sangamo Therapeutics Inc. Browse to the bottom of this webpage for potential risks for Sangamo Therapeutics Inc based on industry, geography and size. If you work at Sangamo Therapeutics Inc and you wish to use your ESG rating, please contact us.
Sangamo Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.5; made up of an environmental score of 0.0, social score of 0.0 and governance score of 1.6.
0.5
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1898 | Zota Health Care Ltd | 0.7 | Low |
| 1898 | cbdMD Inc | 0.7 | Low |
| 1924 | Sangamo Therapeutics Inc | 0.5 | Low |
| 1924 | Beximco Pharmaceuticals Ltd | 0.5 | Low |
| 1924 | Acucela Inc | 0.5 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Sangamo Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Sangamo Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Sangamo Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Sangamo Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Sangamo Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Sangamo Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Sangamo Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Sangamo Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Sangamo Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Sangamo Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Sangamo Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Sangamo Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Sangamo Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Sangamo Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Sangamo Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Sangamo Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Sangamo Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Sangamo Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.